Beta Bionics, Inc. Chief Commercial Officer Mark Hopman filed a Form 4 on October 28, 2026, disclosing the sale of 821 shares of common stock on October 26, 2026.

Key Highlights

  • Reporting person: Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc. (NASDAQ:BBNX)
  • Transaction: 821 shares of common stock disposed of (transaction code S) on October 26, 2026
  • Sale price: $20 per share
  • Remaining ownership: 54,513 shares of common stock held directly following the transaction
  • Rule 10b5-1 Plan: The sale was made pursuant to a Rule 10b5-1 plan adopted on June 10, 2026
  • Filing signed by: Thomas Sohn, Attorney-in-Fact, on October 28, 2026

Hopman's October 2026 Common Stock Sale Under 10b5-1 Plan

According to the Form 4 filing, Mark Hopman, serving as Chief Commercial Officer of Beta Bionics, Inc. (NASDAQ:BBNX), disposed of 821 shares of the company's common stock on October 26, 2026, at a price of $20 per share. The filing indicates that the transaction was made pursuant to a Rule 10b5-1 plan, which the filing states was "adopted on June 10, 2026." The form also carries a checked box confirming the transaction was made under a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Following the reported transaction, Hopman beneficially owned 54,513 shares of Beta Bionics common stock directly, according to the filing. No derivative securities transactions were reported in Table II of the form. The filing was submitted by Thomas Sohn as Attorney-in-Fact on October 28, 2026, two days after the reported transaction date.

What Was Disclosed

The filing disclosed a single sale of 821 shares of Beta Bionics common stock by Chief Commercial Officer Mark Hopman at $20 per share on October 26, 2026, under a pre-established Rule 10b5-1 plan, leaving him with 54,513 directly held shares.